ARMK vs IESC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARMK's deterministic health signals are concerning, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no available Altman Z-Score to confirm solvency safety. The stock trades at a significant premium to its Graham Number of $18.06 and intrinsic value of $8.47, supported by strong revenue growth and analyst optimism, but profitability and earnings trends are inconsistent. While the company shows top-line momentum and operates efficiently relative to peers in a highly leveraged sector, weak margins, declining earnings, and technical bearishness temper enthusiasm. Analysts recommend a 'buy', yet insider sentiment and trading activity are neutral, suggesting no strong conviction from insiders.
IESC exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally low Debt/Equity ratio of 0.07. While the company demonstrates elite profitability (ROE 41.74%) and robust earnings growth (65.8% YoY), the stock is currently trading at a premium, exceeding both its Intrinsic Value ($496.78) and the analyst target price ($458.00). The divergence between stellar operational performance and bearish insider sentiment/technical trends suggests the stock may be overextended after its massive 1-year run (+194.9%).
Compare Another Pair
Related Comparisons
ARMK vs IESC: Head-to-Head Comparison
This page compares Aramark (ARMK) and IES Holdings, Inc. (IESC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.